Analysts Set Aquestive Therapeutics, Inc. (NASDAQ:AQST) Target Price at $11.00

Aquestive Therapeutics, Inc. (NASDAQ:AQST) has earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $11.00.

Several equities research analysts recently weighed in on the stock. Cantor Fitzgerald initiated coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Friday, December 20th. Finally, Leerink Partners boosted their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th.

Institutional Trading of Aquestive Therapeutics

Large investors have recently added to or reduced their stakes in the business. Northern Trust Corp lifted its position in shares of Aquestive Therapeutics by 3.1% during the 4th quarter. Northern Trust Corp now owns 599,812 shares of the company’s stock valued at $2,135,000 after acquiring an additional 18,199 shares during the last quarter. Aquatic Capital Management LLC boosted its position in shares of Aquestive Therapeutics by 400.9% in the 4th quarter. Aquatic Capital Management LLC now owns 62,612 shares of the company’s stock valued at $223,000 after purchasing an additional 50,112 shares during the period. Price T Rowe Associates Inc. MD increased its stake in Aquestive Therapeutics by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company’s stock worth $99,000 after purchasing an additional 3,821 shares in the last quarter. Bracebridge Capital LLC raised its holdings in Aquestive Therapeutics by 7.2% during the 4th quarter. Bracebridge Capital LLC now owns 459,216 shares of the company’s stock worth $1,635,000 after buying an additional 30,645 shares during the period. Finally, Stifel Financial Corp lifted its stake in Aquestive Therapeutics by 315.4% during the fourth quarter. Stifel Financial Corp now owns 398,561 shares of the company’s stock valued at $1,419,000 after buying an additional 302,617 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Price Performance

Aquestive Therapeutics stock opened at $3.32 on Friday. The company has a market cap of $302.72 million, a PE ratio of -7.38 and a beta of 2.67. Aquestive Therapeutics has a 12 month low of $2.24 and a 12 month high of $6.23. The company has a fifty day moving average price of $3.33 and a two-hundred day moving average price of $4.19.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.